EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dexmedetomidine and Apigenin Combination Mitigates Memory Deficits Caused by Microglial Activation and Hippocampal Neurogenesis Impairment in Methotrexate‐Induced Chemo‐Brain in Rats

Einas M Yousef iD, Omar Mohsen Eldemerdash iD, Mahmoud A Senousy iD, Mohamed Taha iD, Haidy Mohammed iD, Ismail Mohamed Elshaffei iD

Neural Plasticity · 2026-01 · 2026 (1)

DOI: 10.1155/np/9434180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neural Plasticity, online erschienen am 11.05.2026. Verfasst von Einas M Yousef und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Genetics, College of Medicine, Alfaisal University, Riyadh, 11533, Saudi Arabia, alfaisal.edu. Hauptthemen laut MEDLINE: Neurogenesis, Hippocampus, Microglia, Memory Disorders. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alfaisal University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dexmedetomidine (Dex), an α2‐adrenergic receptor agonist, and apigenin (Api), a naturally occurring bioflavonoid, have recently shown neuroprotective effects in experimental models of methotrexate (MTX)‐induced neurotoxicity; however, the impact of their combined administration has not yet been elucidated. This study investigated the effects of Dex on microglial activation, neuroinflammation, and apoptosis, and the role of Api in hippocampal neurogenesis, along with its combined effects via the miR‐15a/ROCK‐1/ERK1/2/CREB/BDNF signaling cascade. Male Sprague Dawley rats were randomly assigned into: a normal control group, Dex and Api‐control groups, which received Dex or Api daily for 30 days, an MTX‐only group that received MTX and leucovorin (LCV), Dex or Api cotreated groups received either Dex or Api with MTX and LCV, and a Dex + Api cotreated group received both drugs with MTX and LCV. Dex improved cognitive function by attenuating microglial activation. Api mitigated hippocampal neurogenesis, as shown by decreased Ki‐67 and doublecortin (DCX) expression. Compared with Dex or Api alone, the combined treatment had more favorable effects on novel object recognition (NOR), miR‐15a, ROCK‐1, ERK1/2, histopathological changes, and Ki‐67 neurogenesis marker over Api or Dex monotherapy, and improved CREB/BDNF signaling over Dex alone. However, no additional favorable effects on microglial activation, redox balance, IL‐1β, or apoptosis were observed. The combination of Dex and Api exhibits more pronounced neuroprotective effects by potentiating modulation of the miR‐15a/ROCK‐1/ERK1/2/CREB/BDNF signaling cascade, improving cognitive behavior, and enhancing hippocampal neurogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeurogenesisHippocampusMicrogliaMemory DisordersMethotrexateApigeninNeuroprotective AgentsAnimalsMaleRats, Sprague-DawleyRatsDoublecortin ProteinDrug Therapy, Combination

Substanzen

MethotrexateDcx protein, ratDoublecortin ProteinApigeninNeuroprotective Agents

Autor:innen und Institutionen

  • Department of Anatomy and Genetics, College of Medicine, Alfaisal University, Riyadh, 11533, Saudi Arabia, alfaisal.edu.
  • Department of Histology and Cell Biology, Faculty of Medicine, Menoufia University, 3251, Shebin Elkom, Menoufia, Egypt, menofia.edu.eg.
  • Department of Biochemistry, Faculty of Pharmacy, Misr International University (MIU), Cairo, Egypt, miuegypt.edu.eg.
  • Department of Molecular Biochemistry, Institute of Biochemistry, Universität Stuttgart, Stuttgart, D-70569, Germany, uni-stuttgart.de.
  • Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt, cu.edu.eg.
  • Department of Biochemistry, Faculty of Pharmacy and Drug Technology, Egyptian Chinese University, Cairo, 11786, Egypt.

ORCID-Profile: Einas M Yousef, Omar Mohsen Eldemerdash, Mahmoud A Senousy, Mohamed Taha, Haidy Mohammed, Ismail Mohamed Elshaffei

Förderung

  • Alfaisal University

Zitieren

APA

Yousef, E. M., Eldemerdash, O. M., Senousy, M. A., Taha, M., Mohammed, H., & Elshaffei, I. M. (2026). Dexmedetomidine and Apigenin Combination Mitigates Memory Deficits Caused by Microglial Activation and Hippocampal Neurogenesis Impairment in Methotrexate‐Induced Chemo‐Brain in Rats. Neural Plasticity, 2026(1). https://doi.org/10.1155/np/9434180

Vancouver

Yousef EM, Eldemerdash OM, Senousy MA, Taha M, Mohammed H, Elshaffei IM. Dexmedetomidine and Apigenin Combination Mitigates Memory Deficits Caused by Microglial Activation and Hippocampal Neurogenesis Impairment in Methotrexate‐Induced Chemo‐Brain in Rats. Neural Plasticity. 2026;2026(1). doi:10.1155/np/9434180

BibTeX
@article{Yousef2026,
  author = {Yousef, Einas M and Eldemerdash, Omar Mohsen and Senousy, Mahmoud A and Taha, Mohamed and Mohammed, Haidy and Elshaffei, Ismail Mohamed},
  title = {Dexmedetomidine and Apigenin Combination Mitigates Memory Deficits Caused by Microglial Activation and Hippocampal Neurogenesis Impairment in Methotrexate‐Induced Chemo‐Brain in Rats},
  journal = {Neural Plasticity},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/np/9434180}
}
Kostenlos starten →